Cargando…
Romosozumab and cardiovascular safety in Japan
Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Osteoporosis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486612/ https://www.ncbi.nlm.nih.gov/pubmed/34632110 http://dx.doi.org/10.1016/j.afos.2021.09.002 |
_version_ | 1784577779460734976 |
---|---|
author | Takeuchi, Yasuhiro |
author_facet | Takeuchi, Yasuhiro |
author_sort | Takeuchi, Yasuhiro |
collection | PubMed |
description | Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse events. Further relevant investigations are essential to understand whether romosozumab is actually involved in the development of cardiovascular events or not. We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice. |
format | Online Article Text |
id | pubmed-8486612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean Society of Osteoporosis |
record_format | MEDLINE/PubMed |
spelling | pubmed-84866122021-10-07 Romosozumab and cardiovascular safety in Japan Takeuchi, Yasuhiro Osteoporos Sarcopenia Review Article Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse events. Further relevant investigations are essential to understand whether romosozumab is actually involved in the development of cardiovascular events or not. We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice. Korean Society of Osteoporosis 2021-09 2021-09-09 /pmc/articles/PMC8486612/ /pubmed/34632110 http://dx.doi.org/10.1016/j.afos.2021.09.002 Text en © 2021 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Takeuchi, Yasuhiro Romosozumab and cardiovascular safety in Japan |
title | Romosozumab and cardiovascular safety in Japan |
title_full | Romosozumab and cardiovascular safety in Japan |
title_fullStr | Romosozumab and cardiovascular safety in Japan |
title_full_unstemmed | Romosozumab and cardiovascular safety in Japan |
title_short | Romosozumab and cardiovascular safety in Japan |
title_sort | romosozumab and cardiovascular safety in japan |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486612/ https://www.ncbi.nlm.nih.gov/pubmed/34632110 http://dx.doi.org/10.1016/j.afos.2021.09.002 |
work_keys_str_mv | AT takeuchiyasuhiro romosozumabandcardiovascularsafetyinjapan |